We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
ViroPharma and Wyeth have announced that while the analysis of data from their Phase Ib study of HCV-796, an investigational oral non-nucleoside hepatitis C virus (HCV) polymerase inhibitor, in combination with pegylated interferon is still ongoing, data indicate that HCV-796 has achieved a proof-of-concept milestone.
Raven biotechnologies has announced preliminary results from an ongoing Phase I clinical trial of RAV12, its therapeutic antibody in development for the treatment of adenocarcinomas.
Depomed has completed a Phase I clinical trial to evaluate the delivery and absorption of a controlled-release version of a compound currently used to treat gastroesophageal reflux disease (GERD).
Mylan Laboratories announced that the FDA has granted tentative approval to its abbreviated new drug application for venlafaxine hydrochloride tablets 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg.